[{"id":"2a648675-5366-434b-9eca-31ea418b2eb1","acronym":"","url":"https://clinicaltrials.gov/study/NCT00355238","created_at":"2021-01-18T01:13:50.252Z","updated_at":"2024-07-02T16:35:27.336Z","phase":"Phase 2","brief_title":"A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer","source_id_and_acronym":"NCT00355238","lead_sponsor":"Bristol-Myers Squibb","biomarkers":" AFP","pipe":"","alterations":" ","tags":["AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e brivanib alaninate (BMS-582664)"],"overall_status":"Completed","enrollment":" Enrollment 137","initiation":"Initiation: 12/31/2006","start_date":" 12/31/2006","primary_txt":" Primary completion: 04/30/2010","primary_completion_date":" 04/30/2010","study_txt":" Completion: 04/30/2010","study_completion_date":" 04/30/2010","last_update_posted":"2023-12-01"},{"id":"e0240271-2ac4-47c2-9956-8f3eec7a44d0","acronym":"","url":"https://clinicaltrials.gov/study/NCT00640471","created_at":"2021-01-18T02:22:59.928Z","updated_at":"2024-07-02T16:35:40.878Z","phase":"Phase 3","brief_title":"Cetuximab With or Without Brivanib in Treating Patients With K-Ras Wild Type Tumours and Metastatic Colorectal Cancer","source_id_and_acronym":"NCT00640471","lead_sponsor":"NCIC Clinical Trials Group","biomarkers":" KRAS • BRAF","pipe":" | ","alterations":" RAS wild-type","tags":["KRAS • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • brivanib alaninate (BMS-582664)"],"overall_status":"Completed","enrollment":" Enrollment 750","initiation":"Initiation: 05/12/2008","start_date":" 05/12/2008","primary_txt":" Primary completion: 09/06/2011","primary_completion_date":" 09/06/2011","study_txt":" Completion: 01/10/2013","study_completion_date":" 01/10/2013","last_update_posted":"2023-08-04"}]